📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. (2019)

First Author: Stein EM

Attributed to: Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Acute Myelodi Leukaemia (and Solid Tumours). funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood-2018-08-869008

PubMed Identifier: 30510081

Publication URI: http://europepmc.org/abstract/MED/30510081

Type: Journal Article/Review

Volume: 133

Parent Publication: Blood

Issue: 7

ISSN: 0006-4971